Literature DB >> 7296496

Follow-up study of thymomas with special reference to their clinical stages.

A Masaoka, Y Monden, K Nakahara, T Tanioka.   

Abstract

Follow-up data were obtained for 96 cases of thymoma. The one-year survival rate was 84.3%, the three-year 77.1%, the five-year 74.1%, and the ten-year 57.1%. The five-year survival rate of total resection group was 88.9%; that of non-radically treated group was 44.4%. Clinical stages were defined: Stage I--macroscopically encapsulated and microscopically no capsular invasion; Stage II--1. macroscopic invasion into surrounding fatty tissue of mediastinal pleura, or 2. microscopic invasion into capsule; Stage III--macroscopic invasion into neighboring organ; Stage IVa--pleural or pericardial dissemination; Stage IVb--lymphogenous or hematogenous metastasis. Five-year survival rates of each clinical stage were 92.6% in Stage I, 85.7% in Stage II, 69.6% in Stage III, and 50% in Stage IV. Recurrence after total resection was found in six of 69 cases. Seven of 13 patients treated by subtotal resection survived more than five years with postoperative radiotherapy.

Entities:  

Mesh:

Year:  1981        PMID: 7296496     DOI: 10.1002/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  332 in total

Review 1.  Recurrent thymic carcinoid tumor in the pleural cavity. 2 cases of long-term survivors.

Authors:  M Tsuchida; Y Yamato; T Hashimoto; M Saito; J Hayashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-11

2.  Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Authors:  Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

3.  Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.

Authors:  Nicola M Neary; Ariel Lopez-Chavez; Brent S Abel; Alison M Boyce; Nicholas Schaub; King Kwong; Constantine A Stratakis; Cesar A Moran; Giuseppe Giaccone; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

4.  [Metastatic lung tumor developing 15 years after resection of invasive thymoma].

Authors:  R Suzuki; K Kondo; H Hongo; T Mori; N Kitamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

5.  Postoperative radiotherapy of patients with thymic epithelial tumors (TET): a retrospective analysis of outcome and toxicity.

Authors:  Matthias Felix Häfner; Falk Roeder; Florian Sterzing; David Krug; Stefan A Koerber; Jutta Kappes; Hans Hoffmann; Alla Slynko; Jürgen Debus; Marc Bischof
Journal:  Strahlenther Onkol       Date:  2014-08-26       Impact factor: 3.621

Review 6.  Pediatric thymomas: report of two cases and comprehensive review of the literature.

Authors:  Annabelle L Fonseca; Doruk E Ozgediz; Emily R Christison-Lagay; Frank C Detterbeck; Michael G Caty
Journal:  Pediatr Surg Int       Date:  2013-12-10       Impact factor: 1.827

7.  18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.

Authors:  Anish Thomas; Esther Mena; Karen Kurdziel; David Venzon; Sean Khozin; Arlene W Berman; Peter Choyke; Eva Szabo; Arun Rajan; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

8.  Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

Authors:  Thomas Neuhaus; Joachim Luyken
Journal:  Target Oncol       Date:  2012-10-23       Impact factor: 4.493

9.  Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma.

Authors:  Yukari Miki; Kana Hamada; Tadashi Yoshino; Katsuya Miyatani; Kiyoshi Takahashi
Journal:  Virchows Arch       Date:  2014-05-07       Impact factor: 4.064

10.  Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21.

Authors:  Y Hayashi; N Ishii; C Obayashi; K Jinnai; K Hanioka; Y Imai; H Itoh
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.